Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.
Antigens, Neoplasm
/ genetics
CD4 Antigens
/ metabolism
Cisplatin
/ therapeutic use
Enzyme-Linked Immunospot Assay
Head and Neck Neoplasms
/ immunology
Humans
Immune Tolerance
Immunophenotyping
Lung Neoplasms
/ immunology
Neoadjuvant Therapy
/ methods
Peptides
/ genetics
T-Cell Antigen Receptor Specificity
T-Lymphocytes, Regulatory
/ immunology
Telomerase
/ genetics
Th1 Cells
/ immunology
Chemoradiation
Immune suppressive cells
Tumor-specific T cell response
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
18 06 2021
18 06 2021
Historique:
received:
15
01
2021
accepted:
13
05
2021
entrez:
19
6
2021
pubmed:
20
6
2021
medline:
15
2
2022
Statut:
epublish
Résumé
The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer. Peripheral blood mononuclear cells were collected at baseline and 1 month after treatment from blood samples of 29 patients treated with cisplatin-based chemoradiotherapy for lung or head and neck cancer. Circulating anti-tumor Th1 response was assessed by the ELISpot assay using a mixture of human leucocyte antigen (HLA) class II restricted peptides derived from telomerase (TERT). Phenotyping of circulating immunosuppressive cells (Treg and MDSC) was performed by flow cytometry. A significant increase of circulating Treg was observed in 60% of patients after CRT The mean rate of Treg was 3.1% versus 4.9% at baseline and after CRT respectively, p = 0.0015). However, there was a no significant increase of MDSC rate after CRT. In contrast, a decrease of tumor-specific Th1 response was documented in 7 out of 10 evaluated patients. We found high frequency of pre-existing tumor-specific Th1 response among patients with objective response after CRT compared to non-responders. Cisplatin-based CRT promotes expansion of Treg and decrease of circulating anti-tumor Th1 response in peripheral blood. The balance towards a sustained specific anti-tumor T-cell response appears to be associated with response to CRT.
Sections du résumé
BACKGROUND
The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer.
MATERIALS AND METHODS
Peripheral blood mononuclear cells were collected at baseline and 1 month after treatment from blood samples of 29 patients treated with cisplatin-based chemoradiotherapy for lung or head and neck cancer. Circulating anti-tumor Th1 response was assessed by the ELISpot assay using a mixture of human leucocyte antigen (HLA) class II restricted peptides derived from telomerase (TERT). Phenotyping of circulating immunosuppressive cells (Treg and MDSC) was performed by flow cytometry.
RESULTS
A significant increase of circulating Treg was observed in 60% of patients after CRT The mean rate of Treg was 3.1% versus 4.9% at baseline and after CRT respectively, p = 0.0015). However, there was a no significant increase of MDSC rate after CRT. In contrast, a decrease of tumor-specific Th1 response was documented in 7 out of 10 evaluated patients. We found high frequency of pre-existing tumor-specific Th1 response among patients with objective response after CRT compared to non-responders.
CONCLUSION
Cisplatin-based CRT promotes expansion of Treg and decrease of circulating anti-tumor Th1 response in peripheral blood. The balance towards a sustained specific anti-tumor T-cell response appears to be associated with response to CRT.
Identifiants
pubmed: 34144673
doi: 10.1186/s12865-021-00429-5
pii: 10.1186/s12865-021-00429-5
pmc: PMC8212531
doi:
Substances chimiques
Antigens, Neoplasm
0
CD4 Antigens
0
Peptides
0
Telomerase
EC 2.7.7.49
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Références
Cancer Res. 2016 Jul 15;76(14):4100-12
pubmed: 27197194
J Immunother Cancer. 2019 Jun 25;7(1):160
pubmed: 31238970
Ann Surg Oncol. 2014 Feb;21(2):670-6
pubmed: 24310792
Blood. 2003 Feb 1;101(3):1038-44
pubmed: 12393675
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Int J Mol Sci. 2020 Sep 17;21(18):
pubmed: 32957741
Oncoimmunology. 2016 Dec 23;6(2):e1267095
pubmed: 28344877
JAMA Oncol. 2015 Dec;1(9):1325-32
pubmed: 26270858
Oncoimmunology. 2013 Mar 1;2(3):e23430
pubmed: 23802085
Cancer Immunol Res. 2019 Mar;7(3):355-362
pubmed: 30659053
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Am J Cancer Res. 2020 Feb 01;10(2):440-453
pubmed: 32195019
Oncoimmunology. 2015 May 28;4(11):e1046028
pubmed: 26451318
J Immunother Cancer. 2019 Jan 15;7(1):10
pubmed: 30646957
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
J Clin Oncol. 2014 Apr 20;32(12):1173-9
pubmed: 24663053
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Eur J Cancer. 2016 Nov;67:141-151
pubmed: 27669501
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
Radiat Res. 2014 Aug;182(2):170-81
pubmed: 24937779
J Immunol. 2008 Jul 1;181(1):431-9
pubmed: 18566409
Front Oncol. 2012 Oct 26;2:153
pubmed: 23112958
World J Clin Oncol. 2017 Feb 10;8(1):1-20
pubmed: 28246582
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):997-1006
pubmed: 11072156
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Front Oncol. 2012 Aug 06;2:89
pubmed: 22888475
Oncoimmunology. 2016 Feb 18;5(5):e1137416
pubmed: 27467955
FEBS Lett. 2018 Jun;592(12):2023-2031
pubmed: 29749098
J Immunother. 2010 Nov-Dec;33(9):991-8
pubmed: 20948437
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):499-507
pubmed: 17398016
Cancer Lett. 2003 May 15;194(2):221-33
pubmed: 12757980
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Clin Cancer Res. 2013 Dec 1;19(23):6585-96
pubmed: 24097865
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Cancer Immunol Res. 2016 Nov;4(11):895-902
pubmed: 27803050
Blood. 2006 Apr 1;107(7):2871-8
pubmed: 16339406
Eur J Cancer. 1997 Apr;33(5):781-6
pubmed: 9282117
J Thorac Dis. 2018 May;10(Suppl 13):S1447-S1460
pubmed: 29951296
Cell. 2001 Aug 10;106(3):255-8
pubmed: 11509172
J Immunol. 1998 Sep 1;161(5):2195-200
pubmed: 9725211
Clin Cancer Res. 2012 May 15;18(10):2943-53
pubmed: 22407833
Lancet Oncol. 2018 Aug;19(8):1094-1106
pubmed: 30042063
Cancer Res. 2013 May 1;73(9):2782-94
pubmed: 23418320
Nature. 2013 Feb 21;494(7437):361-5
pubmed: 23376950
J Immunol. 1998 Apr 1;160(7):3363-73
pubmed: 9531296
Br J Cancer. 2019 Aug;121(5):405-416
pubmed: 31358938
Clin Cancer Res. 2014 Nov 1;20(21):5384-91
pubmed: 25204552
Front Oncol. 2012 Aug 17;2:90
pubmed: 22912933
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Cancer Immunol Immunother. 2004 Dec;53(12):1135-45
pubmed: 15696611